Topical Vitamin D in Acute Graft Versus Host Disease of the Skin

Completed · Not applicable

Conditions studied: Graft Vs Host Disease

In brief

The purpose of this study is to evaluate the efficacy of Calcipotriene cream. This is a synthetic vitamin D3 derivative for topical use. It is used to treat grade 1-3 acute skin graft versus host disease (GVHD) in hematopoietic stem cell transplant (HSCT) recipients. Calcipotriene will be used as the exclusive topical therapy in addition to standard of care GVHD treatment prescribed for the study subject by the primary physician.

Key facts

Study ID

NCT03093805

Run by

Children's Hospital Medical Center, Cincinnati

People needed

10

Starts

2017-03-15

Expected to finish

2019-03-26

Last updated by the study team

2019-06-12

Who can join

Age: 0 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HSCT recipients with acute Grade I through III GVHD based on Glucksberg criteria. Recipients of multiple transplants are still eligible to participate in this research study.
• Each study subject is to have calcium and vitamin D level prior to starting study, if not obtained within 30 days of beginning treatment.

You may not qualify if…

• Patient with active cellulitis at the start of the treatment.
• Patients with hypercalcemia or vitamin D levels above 100 μg/L.
• Patients with known allergy to any of the topical therapy components.
• Patients who have received previous treatment with topical vitamin D cream.

Where it is running

• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.